Korean startup AbFinder Therapeutics, a developer of biopharmaceutical platforms, has secured seed funding from a fund jointly operated by Yonsei Biohealth Technology Holdings and InnoCube.

Founded in October 2024, AbFinder Therapeutics is a next-generation biopharmaceutical platform company developing proprietary technologies that address key limitations of antibody– and protein-based therapeutics, drawing attention both domestically and internationally. The company is currently advancing an ADC candidate (ABF-P001), a BiTE-based candidate (ABF-P002), and a novel antibody drug pipeline targeting solid tumors.

Yonsei University Biohealth Technology Holdings was established to identify and commercialize outstanding technologies in the bio-medical field, serving as a specialized industry-academia-research holding company for biohealth innovation. InnoCube, a subsidiary of Handok, is a biohealthcare accelerator that supports promising startups with early-stage funding, shared laboratory facilities, and research infrastructure.

AbFinder Therapeutics CEO Sung-Gu Han stated, “This investment will serve as a springboard to validate our platform, rapidly secure revenue, and grow through global patent registrations and licensing deals.”